ProStrakan Group plc is one of Europe's fastest growing specialty
pharmaceutical companies. We are engaged in the development and
commercialisation of prescription medicines for the treatment of unmet
therapeutic needs in major markets. The company
markets a range of products in major EU markets through its commercial
operations based in the UK, Germany, France, Spain, Sweden and BeNeLux and has its headquarters and R&D activities in Galashiels, Scotland.
Interim Management Statement - 15/5/2008
Galashiels, Scotland, 15 May 2008: ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today issues its Interim Management Statement (IMS) for the period 1 January - 15 May 2008.
Click to read more
ProStrakan announces positive results from pivotal US "Fortify" study on Fortigel (2% testosterone gel) - 8/5/2008
ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces positive results from the pivotal US clinical program on Fortigel™ for testosterone replacement therapy in hypogonadal men. Based on these results, ProStrakan expects to re-file Fortigel with the FDA in Q3 2008.
Click to read more
FDA Moves Sancuso PDUFA Date to mid-June - 23/4/2008
ProStrakan Group plc (LSE: PSK), the international specialty pharmaceutical company, today announces that it has received notification from the US Food and Drug Administration (FDA) of its decision to postpone the Action Date under the Prescription Drug User Fee Act (PDUFA) for Sancuso® by approximately six weeks from early May to mid-June 2008. Their decision has been taken as a result of the well-publicised resourcing issues currently being experienced by FDA.
Click to read more
Subscribe
If you would like to receive regular email updates please click here
We are currently recruiting patients in the US for an ongoing Anal Pain Trial. Please visit the site for more information. |
